Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.36 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.36 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6866214 | 0.87 | THRB (0.40) | LPAR1KCNK3KCNK9 | |
| SCHEMBL6863345 | 0.79 | THRB (0.44) | ALDH1A1GAALPAR1 | |
| SCHEMBL6864035 | 0.79 | PPARG (0.40) | ALDH1A1GAACA12CA1CA9 | |
| SCHEMBL18467344 | 0.74 | ALDH1A1 (0.58) | ALDH1A1GAACA12CA1CA9 | |
| SCHEMBL282518 | 0.72 | RORC (0.64) | — | |
| SCHEMBL26521205 | 0.71 | ALDH1A1 (0.48) | ALDH1A1GAACA12CA1CA9 | |
| SCHEMBL145260 | 0.69 | ALDH1A1 (0.51) | ALDH1A1GAACA12CA1CA9 | |
| SCHEMBL13065195 | 0.69 | ALDH1A1 (0.46) | ALDH1A1GAACA12CA1CA9 | |
| SCHEMBL16302366 | 0.69 | CA12 (0.51) | ALDH1A1GAACA12CA1CA9 | |
| SCHEMBL13989144 | 0.69 | ALDH1A1 (0.58) | ALDH1A1GAACA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6803480-B2 | THERAPEUTIC TREATMENT AND/OR PROPHYLAXIS OF ARTERIOSCLEROSIS AND HYPERCHOLESTEROLAEMIA | BAYER AKTIENGESELLSCHAFT (DE) | 2004-10-12 | — | — | US | disclosed |
| US-20030203898-A1 | Therapeutic treatment and/or prophylaxis of arteriosclerosis and hypercholesterolaemia | BAYER AKTIENGESELLSCHAFT (DE) | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203898-A1 | Therapeutic treatment and/or prophylaxis of arteriosclerosis and hypercholesterolaemia | APOB, HMGCR, PCSK9 | ALDH1A1 1351/4885GAA 1550/4885CA12 4256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.